Is mitochondrial peptide MOTS‑C effective or safe for enhancing ovulation or treating ovulatory disorders?

MOTS-C and Ovulatory Disorders

MOTS-c is NOT recommended for treating ovulatory disorders or enhancing ovulation, as there is no clinical evidence supporting its use in humans for reproductive purposes, and it lacks FDA approval for any indication related to ovulation or fertility.

Current Evidence Status

The provided FDA drug labels 1 are for pravastatin (a statin medication), not MOTS-c. This appears to be a labeling error in the evidence database. MOTS-c has no FDA-approved indications and is not an approved pharmaceutical agent for any clinical use.

What the Research Shows (Animal Studies Only)

The available evidence consists entirely of preclinical animal research with no human clinical trials for ovulatory function:

• Male reproductive hormones in rats 2: MOTS-c infusion increased GnRH, testosterone, LH, and FSH in male rats, suggesting potential effects on the reproductive axis. However, this addresses male fertility, not female ovulation.

• Metabolic effects post-ovariectomy 3, 4: Studies showed MOTS-c prevented weight gain and bone loss after ovary removal in mice, but these models represent absence of ovarian function, not restoration of ovulation.

• Gestational diabetes 5: MOTS-c improved glucose metabolism in pregnant mice with GDM, but this addresses metabolic dysfunction during pregnancy, not ovulation induction.

Evidence-Based Treatment for Ovulatory Disorders

For PCOS/PMOS (Polycystic Ovary Syndrome)

First-line approach 6, 7:

• Lifestyle modification for 3-6 months (weight loss if BMI >25 kg/m²)
• Letrozole is the first-line pharmacologic ovulation induction agent (superior efficacy and safety compared to clomiphene citrate)
• Metformin as adjunct for metabolic optimization in overweight/obese patients

Second-line options 6:

• Gonadotropins with low-dose protocols (FSH 37.5-50 IU/day)
• Laparoscopic ovarian drilling
• IVF with GnRH antagonist protocols

For Functional Hypothalamic Amenorrhea

Primary treatment 8:

• Correct energy imbalance: increase caloric intake, improve nutrition, reduce excessive exercise (often requires weight gain)
• Cognitive behavioral therapy for psychological support
• Avoid oral contraceptives for the sole purpose of regaining menses (they mask return of spontaneous ovulation)

For fertility 8:

• Pulsatile GnRH therapy (first-line when available)
• Gonadotropin therapy (second-line)
• Clomiphene citrate if sufficient endogenous estrogen present

Critical Pitfalls

1. No human data exists for MOTS-c in ovulatory disorders—using it would be entirely experimental
2. Safety profile unknown in women of reproductive age or during conception attempts
3. Mechanism unclear for human ovarian function despite animal studies showing metabolic benefits
4. The animal studies showing reproductive hormone effects 2 were in males, not females with ovulatory dysfunction

Bottom Line

Use evidence-based ovulation induction protocols with letrozole as first-line 6, 7 for PCOS or energy balance restoration 8 for hypothalamic amenorrhea. MOTS-c remains an investigational peptide without established role in reproductive medicine.